On Wednesday, October 11, 2023, we teamed up with Cyberport, HKMHDIA, and UMP Innov Centre to host the “Bright Ideas, Strong Barriers: A Patenting Masterclass” seminar, both in-person and online. Jennifer, our Managing Director, and Pauli, our Principal, took the stage and delivered presentations on the fundamentals of intellectual property (IP) and the challenges faced in MedTech/Healthcare innovation within the GBA and China.

We were privileged to have a distinguished panel of experts who generously shared their experiences and insights on the topic of “MedTech Innovations and Intellectual Property Protection.” Our esteemed panelists included Ronnie Li from UMP Healthcare Group as the moderator, Dr. Lydia Leung from HKMHDIA and Belun Technology, Mr. Justin Chan from Gense Technologies, Ms. Kim Chow from LinkAIQ, and our very own Managing Director, Ms. Jennifer Che.

At Eagle IP Limited, our mission is to assist both local and foreign inventors in safeguarding their creations and business endeavors. Through seminars like these, we aim to raise awareness about the importance of IP in the technology industry. We eagerly anticipate organizing more IP workshops and events for our community!






我们的过去活动

Recommended Insights

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]

Markush claims in China - what can be arbitrarily deleted during invalidation?

2018年12月4日
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]
Top crossarrow-right